The changing landscape of therapeutic cancer vaccines—novel platforms and neoantigen identification
J Jou, KJ Harrington, MB Zocca, E Ehrnrooth… - Clinical Cancer …, 2021 - AACR
Therapeutic cancer vaccines, an exciting development in cancer immunotherapy, share the
goal of creating and amplifying tumor-specific T-cell responses, but significant obstacles still …
goal of creating and amplifying tumor-specific T-cell responses, but significant obstacles still …
Recent advances and challenges in cancer immunotherapy
C Peterson, N Denlinger, Y Yang - Cancers, 2022 - mdpi.com
Simple Summary Immunotherapy helps a person's immune system to target tumor cells.
Recent advances in cancer immunotherapy, including immune checkpoint inhibition …
Recent advances in cancer immunotherapy, including immune checkpoint inhibition …
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
JW Kjeldsen, CL Lorentzen, E Martinenaite… - Nature medicine, 2021 - nature.com
Abstract Anti-programmed death (PD)-1 (aPD1) therapy is an effective treatment for
metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We …
metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We …
Tumor microenvironment antigens
MH Andersen - Seminars in Immunopathology, 2023 - Springer
The identification and characterization of tumor antigens are central objectives in developing
anti-cancer immunotherapy. Traditionally, tumor-associated antigens (TAAs) are considered …
anti-cancer immunotherapy. Traditionally, tumor-associated antigens (TAAs) are considered …
[HTML][HTML] Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L) 1
K Mortezaee, J Majidpoor - Biomedicine & Pharmacotherapy, 2023 - Elsevier
CD8+ T cells are the front-line defensive cells against cancer. Reduced infiltration and
effector function of CD8+ T cells occurs in cancer and is contributed to defective immunity …
effector function of CD8+ T cells occurs in cancer and is contributed to defective immunity …
Arginase 1–based immune modulatory vaccines induce anticancer immunity and synergize with anti–PD-1 checkpoint blockade
M Aaboe Jørgensen, S Ugel, M Linder Hübbe… - Cancer immunology …, 2021 - AACR
Expression of the L-arginine catabolizing enzyme arginase 1 (ARG1) is a central
immunosuppressive mechanism mediated by tumor-educated myeloid cells. Increased …
immunosuppressive mechanism mediated by tumor-educated myeloid cells. Increased …
Indoleamine 2, 3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated
A Charehjoo, J Majidpoor, K Mortezaee - International …, 2023 - Elsevier
Metabolic alterations occur commonly in tumor cells as a way to adapt available energetic
sources for their proliferation, survival and resistance. Indoleamine 2, 3-dioxygenase 1 …
sources for their proliferation, survival and resistance. Indoleamine 2, 3-dioxygenase 1 …
[HTML][HTML] TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer
M Perez-Penco, SE Weis-Banke, A Schina… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Pancreatic ductal adenocarcinoma (PDAC) is associated with very poor
survival, making it the third and fourth leading cause of all cancer-related deaths in the USA …
survival, making it the third and fourth leading cause of all cancer-related deaths in the USA …
The immunosuppressive role of indoleamine 2, 3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies
Glioblastoma multiforme (GBM) is a fatal brain tumor in adults with a bleak diagnosis.
Expansion of immunosuppressive and malignant CD4+ FoxP3+ GITR+ regulatory T cells is …
Expansion of immunosuppressive and malignant CD4+ FoxP3+ GITR+ regulatory T cells is …
CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment
I Lecoq, KL Kopp, M Chapellier, P Mantas… - …, 2022 - Taylor & Francis
ABSTRACT CCL22 is a macrophage-derived immunosuppressive chemokine that recruits
regulatory T cells through the CCL22: CCR4 axis. CCL22 was shown to play a key role in …
regulatory T cells through the CCL22: CCR4 axis. CCL22 was shown to play a key role in …